Search Result

Results for "

Mitoxantrone diacetate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) BCRP (2) DNA Alkylator/Crosslinker (1) Endogenous Metabolite (7) Isotope-Labeled Compounds (2) Liposome (2) Orthopoxvirus (6) PKC (7) Topoisomerase (9)
By Research Areas:	Cancer (14) Infection (6) Metabolic Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13502

*Mitoxantrone* Maximum Cited Publications 33 Publications Verification Mitozantrone; NSC 301739	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite	Infection Cancer
Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502A

Mitoxantrone dihydrochloride Maximum Cited Publications 33 Publications Verification Mitozantrone dihydrochloride; NSC 301739 dihydrochloride	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite	Infection Cancer
Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502S

Mitoxantrone-d8 Mitozantrone-d₈; NSC 301739-d₈	Isotope-Labeled Compounds Topoisomerase PKC	Cancer
Mitoxantrone-d₈ (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a topoisomerase II inhibitor and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM[1][2].

HY-148702

di-Pal-MTO	Liposome	Cancer
di-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity .

HY-13502B

Mitoxantrone diacetate Mitozantrone diacetate; NSC 301739 diacetate	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite	Infection Cancer
Mitoxantrone diacetate is a potent topoisomerase II inhibitor. Mitoxantrone diacetate also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone diacetate induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone diacetate shows antitumor activity . Mitoxantrone diacetate also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502R

Mitoxantrone (Standard)	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite	Infection Cancer
Mitoxantrone (Standard) is the analytical standard of Mitoxantrone. This product is intended for research and analytical applications. Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502AR

Mitoxantrone (dihydrochloride) (Standard)	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite	Infection Cancer
Mitoxantrone (dihydrochloride) (Standard) is the analytical standard of Mitoxantrone (dihydrochloride). This product is intended for research and analytical applications. Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502AS

Mitoxantrone-d8 dihydrochloride Mitozantrone-d₈(dihydrochloride); NSC 301739-d₈ dihydrochloride	Endogenous Metabolite PKC Apoptosis Topoisomerase Orthopoxvirus Isotope-Labeled Compounds	Infection Cancer
Mitoxantrone-d₈ dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13727

Pixantrone free base BBR 2778 free base	Topoisomerase	Cancer
Pixantrone (BBR 2778 (free base)), a mitoxantrone analog, is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity.

HY-13727B

Pixantrone hydrochloride BBR 2778 hydrochloride	Topoisomerase	Cancer
Pixantrone (BBR 2778 (free base)) hydrochloride, a mitoxantrone analog, is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity .

HY-148701

mono-Pal-MTO	Liposome	Cancer
mono-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity .

HY-169860

BCRP-IN-2	BCRP	Cancer
BCRP-IN-2 has BCRP inhibitory activity and shows even greater inhibition of BCRP after activation by ultraviolet light. BCRP-IN-2 can be a valuable probe for studying the interactions of quinazolinamine derivatives with BCRP, as it stimulates ATP hydrolysis of the BCRP transport protein, increasing the accumulation of mitoxantrone (HY-13502) in H460/MX20 cells with BCRP overexpression .

HY-122416

6,8-Diprenylnaringenin Lonchocarpol A; Senegalensin	BCRP	Metabolic Disease Cancer
6,8-Diprenylnaringenin (Lonchocarpol A; Senegalensin), a hop prenylflavonoid, is a inhibitor of breast cancer resistance protein (BCRP/ABCG2). 6,8-Diprenylnaringenin inhibits ABCG2-mediated efflux of Mitoxantrone, and ³H-Methotrexate transport (IC₅₀=0.41 μM) in HEK293 cells. 6,8-Diprenylnaringenin exhibits some estrogenicity, but its potency is less than 1% of that of 8-Prenylnaringenin .

HY-147740

WEHI-150	DNA Alkylator/Crosslinker	Cancer
WEHI-150 is a replica of mitoxantrone, is a portent DNA interstrand crosslink

HY-111355B

Cholesteryl sulfate sodium	Endogenous Metabolite	Metabolic Disease
Cholesteryl sulfate sodium is an orally available, NPC2-targeted cholesterol biosynthesis agonist. Cholesteryl sulfate sodium activates SREBP2 by competitively binding to NPC2, promoting cholesterol synthesis (EC₅₀=50 μM). Cholesteryl sulfate sodium enhances the self-assembly ability of Mitoxantrone hydrochloride (HY-13502A), while repairing the intestinal mucosal barrier and inhibiting inflammation by regulating serine protease activity and PKCη signaling pathway. Cholesteryl sulfate sodium is a component of the platelet cell membrane and supports platelet adhesion. Cholesteryl sulfate sodium also regulates the activity of selective protein kinase C isoforms and modulates the specificity of PI3K, playing a role in keratinocyte differentiation .

Cat. No.	Product Name	Type

HY-148702

di-Pal-MTO	Drug Delivery
di-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity .

HY-148701

mono-Pal-MTO	Drug Delivery
mono-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13502

*Mitoxantrone* Maximum Cited Publications 33 Publications Verification Mitozantrone; NSC 301739	Infection Quinones Structural Classification Classification of Application Fields Anthraquinones Source classification Endogenous metabolite Disease Research Fields Cancer	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502A

Mitoxantrone dihydrochloride Maximum Cited Publications 33 Publications Verification Mitozantrone dihydrochloride; NSC 301739 dihydrochloride	Infection Quinones Structural Classification Classification of Application Fields Anthraquinones Source classification Endogenous metabolite Disease Research Fields Cancer	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-111355B

Cholesteryl sulfate sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Cholesteryl sulfate sodium is an orally available, NPC2-targeted cholesterol biosynthesis agonist. Cholesteryl sulfate sodium activates SREBP2 by competitively binding to NPC2, promoting cholesterol synthesis (EC₅₀=50 μM). Cholesteryl sulfate sodium enhances the self-assembly ability of Mitoxantrone hydrochloride (HY-13502A), while repairing the intestinal mucosal barrier and inhibiting inflammation by regulating serine protease activity and PKCη signaling pathway. Cholesteryl sulfate sodium is a component of the platelet cell membrane and supports platelet adhesion. Cholesteryl sulfate sodium also regulates the activity of selective protein kinase C isoforms and modulates the specificity of PI3K, playing a role in keratinocyte differentiation .

HY-13502B

Mitoxantrone diacetate Mitozantrone diacetate; NSC 301739 diacetate	Infection Quinones Structural Classification Classification of Application Fields Anthraquinones Source classification Endogenous metabolite Disease Research Fields Cancer	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone diacetate is a potent topoisomerase II inhibitor. Mitoxantrone diacetate also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone diacetate induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone diacetate shows antitumor activity . Mitoxantrone diacetate also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502R

Mitoxantrone (Standard)	Quinones Structural Classification Anthraquinones Source classification Endogenous metabolite	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone (Standard) is the analytical standard of Mitoxantrone. This product is intended for research and analytical applications. Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity . Mitoxantrone also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-13502AR

Mitoxantrone (dihydrochloride) (Standard)	Quinones Structural Classification Anthraquinones Source classification Endogenous metabolite	Topoisomerase PKC Orthopoxvirus Apoptosis Endogenous Metabolite
Mitoxantrone (dihydrochloride) (Standard) is the analytical standard of Mitoxantrone (dihydrochloride). This product is intended for research and analytical applications. Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

HY-122416

6,8-Diprenylnaringenin Lonchocarpol A; Senegalensin	Structural Classification Classification of Application Fields Erythrinasenegalensis DC. Source classification Metabolic Disease Plants Moraceae Flavonoids Leguminosae Humulus lupulus L. Flavonones Phenols Polyphenols Disease Research Fields Cancer	BCRP
6,8-Diprenylnaringenin (Lonchocarpol A; Senegalensin), a hop prenylflavonoid, is a inhibitor of breast cancer resistance protein (BCRP/ABCG2). 6,8-Diprenylnaringenin inhibits ABCG2-mediated efflux of Mitoxantrone, and ³H-Methotrexate transport (IC₅₀=0.41 μM) in HEK293 cells. 6,8-Diprenylnaringenin exhibits some estrogenicity, but its potency is less than 1% of that of 8-Prenylnaringenin .

Cat. No.	Product Name	Chemical Structure

HY-13502S

Mitoxantrone-d8
Mitoxantrone-d₈ (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a topoisomerase II inhibitor and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM[1][2].

HY-13502AS

Mitoxantrone-d8 dihydrochloride
Mitoxantrone-d₈ dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

Mitoxantrone-d8 dihydrochloride

Mitoxantrone-d₈ dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC₅₀ of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity . Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC₅₀s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Mitoxantrone diacetate

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products